NASDAQ:PLUR Pluri Q3 2026 Earnings Results & Report $0.93 -0.01 (-1.06%) Closing price 10/14/2026 03:54 PM EasternExtended Trading$0.94 +0.01 (+1.18%) As of 08:55 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Pluri beat analyst earnings expectations but missed on revenue in its Q3 2026 results, released May 14, 2026. The company reported EPS of -$0.55 versus the -$0.66 consensus estimate, while revenue of $0.17 million fell short of the $0.66 million estimate by $0.49 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateMay 14, 2026TimeAfter Market Closes Pluri EPS ResultsActual EPS-$0.55Consensus EPS -$0.66Beat/MissBeat by +$0.11One Year Ago EPSN/AEPS Beat Rate2 of last 4 quartersPluri Revenue ResultsActual Revenue$0.17 millionExpected Revenue$0.66 millionBeat/MissMissed by -$488.00 thousandYoY Revenue GrowthN/AUpcoming EarningsPluri's next earnings date is estimated for Thursday, November 5, 2026, based on past reporting schedules. Conference Call ResourcesEarnings HistoryCompany Profile Pluri Q3 2026 Earnings FAQ Did Pluri beat earnings estimates for Q3 2026? Pluri (NASDAQ:PLUR) reported earnings of -$0.55 per share for Q3 2026, beating the consensus estimate of -$0.66. The report was announced on Thursday, May 14, 2026. What was Pluri's revenue for Q3 2026? Pluri reported revenue of $0.17 million for Q3 2026, against a consensus estimate of $0.66 million. When is Pluri's next earnings date? Pluri's next earnings date is estimated for Thursday, November 5, 2026. MarketBeat tracks confirmed and estimated earnings dates for Pluri on the company's earnings history page. Pluri Earnings HeadlinesEver After Foods and Roslin Technologies Achieve Major Leap in Cultivated Meat ProductivityOctober 13 at 7:00 AM | globenewswire.comPluri (NASDAQ:PLUR) Shares Climb 5.1% - Here's WhyOctober 8, 2026 | americanbankingnews.comBuffett's Final Warning: "The Dollar Is Going to Hell"On May 3rd, 2025, Warren Buffett looked at his shareholders for the last time and said: "The dollar is going to hell." Ray Dalio agrees. The founder of Bridgewater Associates ($150 billion AUM) calls it a "debt death spiral." But there's a specific asset class and investment system that actually thrives when the dollar collapses.October 15 at 1:00 AM | Decentralized Masters (Ad)Pluri Inc. Reports Earnings Results for the Full Year Ended June 30, 2026September 10, 2026 | marketscreener.comMPluri Announces August 2026 Equity Financing TransactionAugust 28, 2026 | tipranks.comPluri prices $3.3 million offeringAugust 27, 2026 | seekingalpha.comSee More Pluri Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Pluri? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Pluri and other key companies, straight to your email. Email Address About PluriPluri (NASDAQ:PLUR) (NASDAQ: PLUR), formerly known as Pluristem Therapeutics, is a biotechnology company developing cell-based products using its proprietary three-dimensional cell expansion platform. The company’s technology is designed to produce large quantities of allogeneic cells, which are cells intended for use in patients other than the original donor, without requiring a tissue match. Pluri’s research has focused primarily on placenta-derived stromal cells, marketed under the PLX platform. Its development programs have explored potential applications in regenerative medicine, including conditions involving tissue damage, inflammation, blood disorders and immune-related diseases. The company has also investigated cell-based solutions for areas beyond traditional therapeutics, including food technology and agricultural applications. Founded as Pluristem Therapeutics, the company changed its name to Pluri as it broadened its focus beyond drug development. Pluri is based in Haifa, Israel, and its activities have included research collaborations and development efforts aimed at serving international healthcare and biotechnology markets. Yaky Yanay has served as the company’s chief executive officer.View Pluri ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Citi Stock Falls Despite Earnings Beat: What Investors Need to KnowDon’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could DeepenUnitedHealth Beats on Earnings, But Investors Question Growth PathIREN Limited's AI Pivot Gains Traction—But Can Its Data Centers Deliver?PBF Energy's Stunning Rally Faces a Critical TestA Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?Albertsons Is Betting on a Turnaround—But Will It Pay Off? Upcoming Earnings Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026)ICICI Bank (10/17/2026)America Movil (10/20/2026)Netflix (10/20/2026)General Motors (10/20/2026)Chubb (10/20/2026)Capital One Financial (10/20/2026)Intuitive Surgical (10/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
